News | May 19, 2023
Gland Pharma posts Q4 FY23 consolidated PAT at Rs. 78.68 Cr
Gland Pharma has reported total income of Rs. 823.95 crores during the period ended March 31, 2023
Gland Pharma has reported total income of Rs. 823.95 crores during the period ended March 31, 2023
The United States Food and Drug Administration (USFDA) conducted an inspection at Gland Pharma Limited API Facility at JNPC, Visakhapatnam
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
The company has received 1 (ONE) observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.
Gland Pharma believes that they are amongst one of the first to file for this product and may be eligible for 180 days of generic drug exclusivity
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
The injection is used to reverse the effects of the muscle relaxants given to patients during surgery
Subscribe To Our Newsletter & Stay Updated
